From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|February 2, 2022
Daily Medication Pearl: Armodafinil (Nuvigil)
Author(s)Saro Arakelians, PharmD
Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents.
Advertisement
Medication Pearl of the Day: Armodafinil (Nuvigil)
Indication: Armodafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).
Insight:
- Dosing: OSA or narcolepsy 150 mg to 250 mg once a day in the morning.
- Dosage forms: Tablets 50 mg, 150 mg, 200 mg, and 250 mg.
- Adverse events: Most common adverse reactions (³5%) are headache, nausea, dizziness, and insomnia.
- Mechanism of action: Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents, including amphetamine and methylphenidate, although their pharmacologic profile is not identical to that of the sympathomimetic amines.
- Manufacturer: Teva Pharma
Sources:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5